Comprehensive pan-cancer analysis reveals the prognostic value and immunological role of SPIB

Meng Ding¹, Qiufang Li¹, Xiao Tan¹, Liangyua Zhang¹, Jun Tan¹,*, Lan Zheng¹,*

¹Key Laboratory of Physical Fitness and Exercise Rehabilitation of Hunan Province, Hunan Normal University, Changsha, China
*Equal contribution

Correspondence to: Jun Tan, Lan Zheng; email: juntan@hunnu.edu.cn, Lanzheng@hunnu.edu.cn

Keywords: pan-cancer, bioinformatics, prognosis, immune infiltration, TMB, MSI

ABSTRACT

It is well-established that SPIB is essential for the survival of mature B cells, playing a key role in diffuse large B-cell lymphoma, colorectal cancer, and lung cancer. However, no study has hitherto conducted a systematic pan-cancer analysis on SPIB. Herein, we analyzed the differential expression of SPIB in pan-cancer using The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) databases and found that SPIB was significantly upregulated in most cancers. In addition, SPIB was positively or negatively associated with prognosis in different cancers. We found that SPIB was significantly associated with tumor immune infiltration and immune checkpoint genes in more than 35 tumors by TIMER database analysis. In addition, SPIB was negatively correlated with Tumor mutational burden (TMB) and Microsatellite instability (MSI) in most tumors. Finally, GO/KEGG enrichment analysis revealed the possible involvement of SPIB in NF-kappa B and B-cell receptor signaling pathways. In conclusion, our comprehensive pan-cancer analysis of SPIB reveals its important role in tumor immunity, suggesting it has huge prospects for clinical application in cancer therapy.

INTRODUCTION

Current evidence suggests that cancer incidence is increasing, associated with increased burden on society [1]. Despite the clinical success of existing treatments (surgery, radiotherapy, chemotherapy, immunotherapy, and targeted therapy), patient prognosis and survival rates remain low [1, 2]. Therefore, the quest for new tumor markers for the diagnosis and treatment of cancer is essential.

SPIB is an ETS transcription factor involved in B cell receptor-mediated signal transduction [3]. SPIB is expressed in pDCs, CD34+ precursor cells, and mature B cells [4, 5] and is associated with the differentiation of plasmacytoid dendritic cells and intestinal microfold cells [6, 7]. An increasing body of evidence from recently published studies suggests that SPIB plays an important role in tumor development. For instance, SPIB reportedly exerts an inhibitory effect in colorectal cancer cells by activating NFkB and JNK signaling through MAP4K1 [8] and promotes tumor-associated macrophage (TAM) recruitment by enhancing the expression of CCL4 in lung cancer [9]. Moreover, SPIB plays an important role in the abnormal switch reorganization of ABC DLBCL [10]. Overwhelming evidence from tissue microarray-based studies has linked SPIB to ovarian cancer, liver cancer, esophageal squamous cell carcinoma, head and neck squamous cell carcinoma, gastric cancer, and hepatocellular carcinoma [11–16]. Immunotherapy has emerged as a new pillar of cancer treatment, mediating tumor regression by blocking immune checkpoints [17]. Although SPIB has been studied in more than 9 tumors, most studies have focused only on specific cancer types. Therefore, a deeper understanding of the relationship between SPIB...
and the immune microenvironment of different tumors is essential to provide the basis for exploring new immune-related therapeutic targets and clinical treatment of cancer.

In this study, we comprehensively analyzed the prognostic relationship between SPIB expression levels and various cancers based on data mining analysis of various databases, including The Cancer Genome Atlas (TCGA), Genotype Tissue-Expression (GTEx), Human Protein Atlas (HPA), Tumor Immune Estimation Resource (TIMER), and cBioPortal. We also explored the role of SPIB in the immune response to further visualize its prognostic outlook in pan-cancer. Our comprehensive analysis revealed that SPIB has prognostic value in various cancers and plays an important role in tumor immunity by affecting tumor-infiltrating immune cells, TMB and MSI. In addition, potential signaling pathways of SPIB were identified by gene set enrichment analysis (GSEA). In conclusion, we systematically and comprehensively investigated SPIB expression in pan-cancer to screen cancer types with poor prognosis and provide the foothold for future studies.

**MATERIALS AND METHODS**

**Data sources and gene transcription expression analysis**

We obtained the pan-cancer dataset TCGA TARGET GTEx (PANCAN, N = 19131, G = 60499) from the University of California Santa Cruz (UCSC) Xena browser (https://xenabrowser.net/) [18]. The expression data of SPIB in each sample was extracted, and log2(x + 0.001) transformed. Finally, tumor types with less than 3 samples were excluded, and the expression data of 34 tumors were obtained (See Supplementary Table 1 for further details). Differences in expression between normal and tumor samples for each tumor type were calculated, and significant differences were analyzed using unpaired Wilcoxon Rank Sum and Signed Rank Tests.

**Genetic alteration analysis**

Data on genetic alterations (Mutation, Amplification, Deep Deletion) of SPIB in 32 tumors were obtained through the cBioPortal database [19]. The cancer type summary module in the cBioPortal database was used to obtain summary graphs of Mutation, Amplification, and Deep Deletion of genes in TCGA tumors.

**Protein level analysis**

The protein expression levels of SPIB in normal and tumor tissues were analyzed in the Human Protein Atlas (HPA, https://www.proteinatlas.org/) database. The SPIB protein-protein interaction network (PPI) was constructed using the String (https://string-db.org/) database.

**Survival prognosis analysis**

Univariate Cox regression analysis was performed using the R package survival (version 3.2-7) [20]. The coxph function was used to establish a Cox proportional hazards regression model and analyze the prognostic relationship of SPIB in various tumors, while the significance of differences was assessed by the Log-rank test. The analytical data are shown in Supplementary Table 2.

**Immune infiltration and immune checkpoint analysis**

The correlation between SPIB expression and the level of immune cell infiltration was analyzed using the gene expression module of the TIMER2.0 database (http://timer.comp-genomics.org/) [21]. Immune cell types included B cell, CD4 T cell, CD8 T cell, neutrophil, macrophage, and dendritic cell (DC); the analysis results are shown in Supplementary Table 3. Spearman’s correlation analysis was used to assess the relationship between SPIB expression and expression levels of immune checkpoint markers. Sixty markers were identified, including inhibitory (n = 24) and stimulatory (n = 36) markers. In addition, we analyzed the relationship between SPIB expression and immune scores, including StromalScore, ImmuneScore, and ESTIMATEScore. Similarly, scatter plots were used to show the top 6 tumors with significant differences, respectively (Supplementary Table 4).

**Co-expression analysis of immune regulatory genes**

Co-expression analysis of SPIB and immunomodulatory genes, including chemokine (41), receptor (18), MHC (21), Immunoinhibitor (24), and Immunostimulator (46) was performed using the R package limma. The co-expression data are shown in Supplementary Table 5.

**Tumor mutation burden and microsatellite instability analysis**

The dataset for calculating TMB comes from Simple Nucleotide Variation at level 4 of all TCGA samples processed by MuTect2 software (DOI: 10.1038/nature08822). The MSI score for each tumor was derived from a previous study [22]. The TMB of each tumor was calculated using the TMB function of the R package maftools (version 2.8.05). The relationship...
between SAPIB expression and TMB and MSI was analyzed using the Pearson correlation coefficient.

**Gene enrichment analysis**

Using the GO annotations of genes in the R package org.Hs.eg.db (version 3.1.0) as the background, the genes were mapped to the background set, and gene set enrichment analysis was conducted by the R package clusterProfiler (version 3.14.3). The minimum number of gene sets was set to 5 and the maximum to 5000; P-value of <0.05 and FDR of <0.1 were considered statistically significant. The detailed analysis results are shown in Supplementary Table 6. In addition, we extracted the top 100 SPIB-related genes in TCGA by GEPIA2 and analyzed the expression correlation between SPIB and the top 5 targeted genes.

**Statistical analysis**

Correlations between variables were analyzed using Pearson or Spearman analysis. Prognostic survival curves were generated using Kaplan-Meier analysis while applying the log-rank test to estimate statistical significance. The significance level was set at $P < 0.05$. All statistical data analyses were performed using R software version 3.6.4.

**Data availability statement**

All data generated or analyzed during this study are included in this published article (and its Supplementary Information files).

**RESULTS**

**SPIB expression is upregulated in most cancers**

To clarify whether SPIB is associated with cancer, we analyzed the mRNA expression of SPIB in normal and tumor tissues using TCGA and GTEx databases. The results showed that SPIB expression was significantly upregulated in 25 out of 33 cancer types compared to adjacent normal tissues, including GBM, GBMLGG, LGG, BRCA, CESC, LUAD, ESCA, STES, KIRP, KIPAN, PRAD, STAD, KIRC, LUSC, LIHC, WT, SKCM, THCA, OV, PAAD, TGCT, UCS, ALL, LAML and CHOL (Figure 1A, 1B). In contrast, SPIB was significantly downregulated in COAD, COADREAD, READ, and KICH (Figure 1A, 1B). These results suggest that SPIB may function as an oncogenic molecule in various cancers. Although gene mutation is not a sufficient condition for carcinogenesis, carcinogenesis depends on the accumulation of gene mutations. Therefore, examining genetic alterations associated with the SPIB gene in cancer patients is essential. We performed a comparative analysis of SPIB using the cBioPortal database and found that SPIB amplification was one of the most important single alterations in Mature B-Cell Neoplasms, ACC, BRCA, BLCA, PAAD, and LIHC (Supplementary Figure 1). In addition, SPIB exhibited the highest mutation frequency in ESCA, UCEC, SKCM, Non-Seminnomatous Germ Cell Tumors, COAD, HNSC, Non-Small Cell Lung Cancer, and SARC (Supplementary Figure 1).

Next, we compared the SPIB gene expression from the TCGA database with the Immunohistochemistry (IHC) results from the HPA database. The results showed negative SPIB expression in normal breast and liver tissues, while tumor tissues showed moderate IHC staining (Figure 2A, 2C). SPIB staining was weak in normal colon tissues, while tumor tissues exhibited strong IHC staining (Figure 2B). In addition, SPIB staining was weak in normal lung tissue, while tumor tissue exhibited moderate staining (Figure 2D). Taken together, these results illustrate the consistency of the TCGA and HPA database results.

**The correlation between SPIB and the prognosis for different tumor types**

We used the coxph function of the R package surv (version 3.2-7) to build a Cox proportional hazards regression model, analyze the prognostic relationship between SPIB expression and prognosis in each tumor, and obtain prognostic significance using a statistical test by Log-rank test [20]. The results showed that SPIB expression affected overall survival (OS) in patients with 16 cancer types, including GBMLGG, LGG, KIRP, KIPAN, GBM, KIRC, THYM, UVM, LAML, BRCA, CESC, LUAD, HNSC, SKCM, SKCM-M, and READ (Figure 3A). In addition, Kaplan-Meier survival analysis showed that reduced SPIB expression correlated with poor OS in LAML, BRCA, CESC, LUAD, HNSC, SKCM, SKCM-M, and READ (Figure 3B). Meanwhile, increased SPIB expression correlated with a poor OS in GBMLGG, LGG, KIRP, KIPAN, GBM, KIRC, THYM, and UVM (Figure 3C).

In addition, we analyzed the correlation between SPIB expression and patient DSS. The results showed that SPIB expression affected Disease-Specific Survival (DSS) in 15 cancer types, including GBMLGG, LGG, KIRP, KIPAN, GBM, KIRC, THYM, UVM, CESC, LUAD, HNSC, SKCM, SKCM-M, READ, and OV (Figure 4A). Kaplan-Meier analysis indicated that decreased SPIB expression correlated with a poor prognosis in CESC, LUAD, HNSC, SKCM, SKCM-M, READ, and OV, whereas increased SPIB expression was associated with poor prognosis in GBMLGG, LGG,
KIRP, KIPAN, GBM, KIRC, THYM, and UVM (Figure 4B, 4C).

Besides, we analyzed the relationship between SPIB expression and patient Disease-Free Interval (DFI). The results showed that SPIB expression affected DFI in patients with 3 cancer types, including COADREAD, OV, and READ (Figure 5A). Kaplan-Meier analysis showed that reduced SPIB expression correlated with a poor prognosis in COADREAD, OV, and READ (Figure 5B).

Finally, we analyzed the correlation between SPIB expression and patient Progression-Free Interval (PFI). The results showed that SPIB expression affected PFI in patients with 12 cancer types, including GBMLGG, LGG, KIRP, KIPAN, GBM, UVM, BRCA, LUAD, HNSC, SKCM, SKCM-M, and OV (Supplementary Figure 2A). Kaplan-Meier analysis showed that reduced SPIB expression in GBMLGG, LGG, KIRP, KIPAN, GBM, and UVM correlated with a poor prognosis, whereas increased SPIB expression was associated with poor prognosis in BRCA, LUAD, HNSC, SKCM, SKCM-M, and OV (Supplementary Figure 2B, 2C). In conclusion, these data suggest that SPIB expression determines the prognosis of patients with different types of cancers, in terms of OS, DSS, DFI or PFI.

Figure 1. Pan-cancer expression profiling of SPIB. (A, B) Differential expression of SPIB in 34 cancers based on TCGA and GTEx databases, blue represents normal tissues, and red represents tumor tissues. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. P-value P < 0.05 was considered statistically significant.
High SPIB expression is associated with immune infiltration of multiple tumors

To elucidate the association between SPIB expression and specific immune cell types in pan-cancer, we evaluated the correlation between SPIB expression and immune cell infiltration in pan-cancer based on the TIMER database. We obtained six types of immune cell infiltration scores for 9,406 tumor samples from 38 cancer types and found that high SPIB expression was significantly associated with immune infiltration in 35 tumors (Figure 6A). SPIB expression was associated

Figure 2. Comparison of SPIB expression in breast, colon, liver, and lung tissues by immunohistochemistry. (A) Breast tissue. (B) Colon tissue. (C) Liver tissue. (D) Lung tissue, including lung adenocarcinoma (LUAD) and lung squamous carcinoma (LUSC). For the violin plot, red is cancer samples and blue is normal samples. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
with B cell, CD4 T cell, CD8 T cell, neutrophil, macrophage, and DC in 32, 33, 20, 31, 25, and 32 tumors, respectively (Figure 6A). In addition, we selected 60 immune checkpoint genes for analysis, including inhibitory ($n = 24$) and stimulatory ($n = 36$) genes. Interestingly, the results of immune checkpoint analysis showed that SPIB expression was positively correlated with most immune checkpoint genes (Figure 6B). In this respect, more than 50 immune checkpoint genes were positively correlated with SPIB expression in LIHC, KIPAN, PRAD, OV, THCA, BRCA, COADREAD, LUAD, BLCA, HNSC, PAAD, and COAD (Figure 6B). In addition, in DLBC, the expression of SPIB was least correlated with the immune checkpoint genes (Figure 6B). To further assess the role of SPIB in the tumor immune microenvironment, we analyzed the relationship between SPIB expression and immune infiltration score in tumors using ESTIMATE. The most significant positive correlation between SPIB expression and immune infiltration was found in UVM, THCA, KIPAN, SKCM, BLCA, and SKCM-M (Figure 6C).

In addition, we analyzed the relationship between SPIB expression and immune-related genes in different tumors, including chemokines, chemokine receptors, MHC, immunosuppression, and immune activation. The results showed that most immune-related genes were co-expressed with SPIB (Supplementary Figure 3). Interestingly, most tumors were positively correlated with SPIB except for ALL, DLBC, and UCS (Supplementary Figure 3). Overall, our results suggest that SPIB plays a key role in immune infiltration and immune escape in most tumors.

**SPIB expression negatively correlates with TMB and MSI in a variety of tumors**

Tumor Mutational Burden (TMB) and Microsatellite Instability (MSI) are well-established as key markers
for immunotherapy [23, 24]. Therefore, we evaluated the correlation of SPIB expression with TMB and MSI. The results showed that SPIB expression was correlated positively with TMB of THYM and negatively with TMB of LUAD, LIHC, TGCT, PCPG, and CHOL (Figure 7A). In addition, SPIB expression correlated positively with the MSI of THYM and negatively with the TMB of GGBLGG, KIPAN, STAD, PRAD, UCEC, HNSC, PAAD, UCS, and DLBC (Figure 7B).

SPIB-related genes mainly mediate immune-related pathways

Finally, we investigated the molecular mechanisms underlying the occurrence of SPIB in tumors. We screened the proteins interacting with SPIB by STRING database and generated a PPI interaction network (Figure 8A). We found that 10 proteins were directly associated with SPIB. The top 100 genes related to SPIB expression were then obtained using the GEPIA database, and the five genes with the highest correlation were selected, including CD19, CD79A, IL21R, SP140, and TLR10 (Figure 8D). In addition, GO analysis suggested genes associated with SPIB expression were significantly enriched in immune system process, lymphocyte activation, immune response, B cell receptor signaling pathway, and regulation of immune system process (Figure 8B). KEGG analysis showed that genes associated with SPIB expression were enriched in Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Primary immunodeficiency, Human T-cell leukemia virus 1 infection, and B cell receptor signaling pathway (Figure 8C). In addition, SPIB had a strong positive correlation with the above five genes in most cancer types (Figure 8E).

---

**Figure 4.** Relationship between SPIB expression and disease-specific survival (DSS) in pan-cancer. (A) Cox regression analysis of SPIB in 44 tumors. (B) Kaplan-Meier OS curves of SPIB expression in patients with CESC, LUAD, HNSC, SKCM, SKCM-M, READ, and OV. (C) Kaplan-Meier OS curves of SPIB expression in patients with GGBLGG, LGG, KIRP, KIPAN, GBM, KIRC, THYM, and UVM. For (B and C), the vertical coordinate is the survival probability, and the horizontal coordinate is the survival time (days).
DISCUSSION

SPIB plays a crucial role in the development of B cells [4]. There is a rich literature available suggesting that SPIB promotes trans-activation of SPI1 to increase glycolytic gene expression and drive the glycolytic process, proliferation, and invasiveness of colon cancer cells [25]. In addition, SPIB is a novel prognostic factor in DLBCL, mediating apoptosis through the PI3K-AKT pathway [26]. Over the years, many studies have linked SPIB to tumors, including lung, gastric, and colorectal cancers. Thus a comprehensive pan-cancer study of SPIB may present a novel perspective on other tumors.

Figure 5. Relationship between SPIB expression and disease-free interval (DFI) in pan-cancer. (A) Cox regression analysis of SPIB in 44 tumors. (B) Kaplan-Meier OS curves of SPIB expression in patients with COADREAD, OV, and READ. The vertical coordinate is the survival probability, and the horizontal coordinate is the survival time (days).
Our study revealed significant differences in SPIB in 29 tumors, including high expression in 25 tumors and low expression in 4 tumors. We also analyzed the protein levels of SPIB expression in breast, colon, liver, and lung tissues by IHC experiments based on the HPA database and confirmed this trend. The importance of identifying tumor-specific targets or features is widely acknowledged, given that individualized treatment based on their characteristics can increase the chances of curing cancer [27]. A pan-cancer analysis is an effective method to discover differential expression and characteristics of tumors. Therefore, we analyzed the relationship between SPIB expression and prognosis in various tumors using TCGA and GTEx databases.

Figure 6. SPIB expression correlates with immune infiltration and immune checkpoint markers. (A) SPIB expression and infiltration levels of various immune cells in the TIMER database. (B) Correlation analysis of SPIB expression levels with the levels of 60 immune checkpoint genes in pan-cancer. (C) SPIB expression in UVM, THCA, KIPAN, SKCM, BLCA, and SKCM-M immune infiltration levels. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
In this study, we found that high SPIB expression correlated with poor OS and DSS in patients with GBMLGG, LGG, KIRP, KIPAN, GBM, KIRC, THYM, and UVM. Low SPIB expression was associated with a poor OS in patients with LAML, BRCA, CESC, LUAD, HNSC, SKCM, and SKCM-M, and poor DSS in patients with CESC, SKCM, and SKCM-M. These findings substantiate that SPIB may serve as a predictor of tumor prognosis. Although these survival analyses have clinical significance and provide a foothold for future studies, in vivo or in vitro validation experiments are lacking. Therefore, the role of SPIB in different types of cancer remains to be further investigated.

Figure 7. Correlation of SPIB expression with tumor mutational load (TMB) and microsatellite instability (MSI) in pan-cancer. (A) The bar graph represents the correlation between SPIB expression and TMB in pan-cancer. (B) The bar graph represents the correlation between SPIB expression and MSI in pan-cancer. P values are from Spearman’s correlation analysis.
In recent years, immunotherapy has become a new pillar in treating tumors. The tumor immune microenvironment is an important component of the tumor microenvironment, and the mechanism by which tumor cells work with the immune microenvironment is important for selecting key molecules for tumor markers and potential drug targets [28, 29]. In addition, tumor-infiltrating lymphocytes, namely tumor-associated macrophages and tumor-infiltrating neutrophils (TIN), play an important role in tumor immunity [30, 31]. These findings corroborate that tumor-infiltrating immune cells play an important role in tumor progression, emphasizing the need to analyze the role of SPIB in the immune microenvironment. We found that SPIB expression was significantly associated with six immune infiltrating cells in most cancers, except UCS, UVM, and DLBC, consistent with previous studies that reported that therapeutic targeting of SPIB/SPI1 promotes the interaction of cancer cells and neutrophils to inhibit aerobic glycolysis and cancer progression [25]. Moreover, it has been shown that SPIB overexpression in mouse models increased infiltration of TAM, especially M2 macrophages, and promoted lung cancer progression [9]. In addition, immune checkpoint genes can directly affect immune cell function [32]. During tumorigenesis, immune checkpoint (IC) signaling is activated by tumors to undergo immune escape and accounts for tumor aggressiveness. Therefore, analyzing the correlation between SPIB expression and immune checkpoint markers could provide new targets for developing novel immunosuppressive agents. In this study, we analyzed more than 50 immune checkpoint genes. The results showed that SPIB expression was positively correlated with immune checkpoints in most tumors, except DLBC, ALL, LAML, and UCS. In addition, our study revealed that SPIB was co-expressed with genes encoding

**Figure 8. SPIB-related gene enrichment and pathway analysis.** (A) SPIB protein network map based on STRING database. (B) GO analysis of the top 100 genes associated with SPIB expression. (C) KEGG analysis of the top 100 genes associated with SPIB expression. (D) Correlation between the most relevant genes for SPIB expression, including PEZ1, GNA12, MAP4, SEPT7 TPST1, and TBL2 of the GEPIA2 tool. (E) Heatmap of genes significantly associated with SPIB expression.
MHC, immune activation, immune suppression, chemokine, and chemokine receptor proteins. These results imply an immunological role for SPIB in various tumors and highlight its potential as a therapeutic target.

TMB is a more accurate and comprehensive potential biomarker. Current evidence suggests that TMB is associated with the occurrence of mutations and the synthesis of abnormal proteins that activate antitumor responses [33]. MSI is a predictive biomarker with potential significance for ICI responses. It has been shown that MSI leads to the accumulation of mutations that result in the formation of neoantigens and the activation of antitumor immune responses [34]. Our study showed that SPIB expression was associated with TMB and MS in THYM, LUAD, LIHC, TGCT, PCPG, CHOL, BMLGG, KIPAN, STAD, PRAD, UCEC, HNSC, PAAD, UCS, and DLBCL. However, further experimental validation of the therapeutic role of SPIB in these cancers is warranted.

We also performed an enrichment analysis of genes related to SPIB expression. IRF4 and SPI1 identified in the SPIB protein interactions network are reportedly involved in B cell differentiation and play a critical and non-redundant role in the adaptive immune response of mature B cells [35, 36]. CREBBP and EP300 are associated with DLBCL, and CREBBP/EP300 mutations induce H3K27 deacetylation and activate the NOTCH signaling pathway, which is closely associated with B-cell malignancies [37]. In addition, the Jun protein family members are involved in the constitutive dimer AP-1. AP-1 activity is involved in various cellular processes; for instance, AP-1 plays a crucial role in several aspects of the immune system, such as T cell activation, T helper (Th) differentiation, T cell incompetence, and failure [38]. MAPKs regulate various cellular activities in cancer progression, including proliferation, apoptosis, and immune escape, and blocking upstream kinases is an important therapeutic strategy [39]. An increasing body of evidence suggests that TLP (TBP-2), a family member of TBP, is a tumor suppressor gene that plays a key role in DC-induced T-cell responses [40, 41]. GATA1 reportedly regulates the basal transcription of mSTING genes and plays a key role in the pathogenesis of autoimmune diseases and cancer [42]. CSNK2A1 is involved in tumorigenesis by phosphorylating various proteins, including SIRT1 [43]. In the present study, we also performed GO and KEGG analyses of genes related to SPIB expression. Overall, the results showed that SPIB was enriched in the immune system process, lymphocyte activation, immune response, B cell receptor signaling pathway, and regulation of the immune system process. These results are consistent with previous studies that SPIB is essential in protective humoral immunity [4]. In addition, SPIB has been associated with tumor suppression via NF-kappa B signaling pathway [8], consistent with our study findings.

In a nutshell, our study demonstrates an important role for SPIB in cancer that is not limited to specific cancer types. We investigated the relationship of SPIB in pan-cancer with prognosis, immune cell infiltration, tumor mutational load, and microsatellite instability and comprehensively assessed its potential as a prognostic biomarker from multiple perspectives. Despite our extensive analytical work, there are many limitations. First of all, the heterogeneity associated with different databases may affect the robustness of our analysis results to a certain extent. Besides, our results are based on public database analysis involving at least 33 cancer types, making experimental validation challenging. Although SPIB promotion of cancer progression has been experimentally validated in colon cancer cells and ABC-DLBCL [25, 44], more clinical or animal experiments are still needed to validate it. Nonetheless, our pan-cancer study analysis of SPIB still provides the basis and novel insights for future studies.

**AUTHOR CONTRIBUTIONS**

MD conceived the project and wrote the first draft. MD, LZ, and QFL participated in the study design and helped draft the manuscript. MD, JT, XT, and LYZ revised the manuscript. MD and LZ performed the literature search and collected the data. MD and LZ analyzed the data. MD, JT, and LZ guided the design of the project and revised key elements of the article. All authors contributed to the article and approved the submitted version.

**ACKNOWLEDGMENTS**

We thank Home for Researchers editorial team (https://www.home-for-researchers.com/) for language editing service.

**CONFLICTS OF INTEREST**

The authors declare no conflicts of interest related to this study.

**ETHICAL STATEMENT**

All experimental protocols were conducted in accordance with relevant guidelines and regulations.
FUNDING

This research was funded by the National Natural Science Foundation of China (grant number 32071175) and The Key scientific research project of the Hunan Education Department (grant number 19A328).

REFERENCES

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71:209–49. https://doi.org/10.3322/caac.21660 PMID:33538338

2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019; 69:7–34. https://doi.org/10.3322/caac.21551 PMID:30620402

3. Garrett-Sinha LA, Su GH, Rao S, Kabak S, Hao Z, Clark MR, Simon MC. PU.1 and Spi-B are required for normal B cell receptor-mediated signal transduction. Immunity. 1999; 10:399–408. https://doi.org/10.1016/s1074-7613(00)80040-0 PMID:10229183

4. Willis SN, Tellier J, Liao Y, Treizise S, Light A, O’Donnell K, Garrett-Sinha LA, Shi W, Tarlinton DM, Nutt SL. Environmental sensing by mature B cells is controlled by the transcription factors PU.1 and SpiB. Nat Commun. 2017; 8:1426. https://doi.org/10.1038/s41467-017-01605-1 PMID:29127283

5. Schotte R, Nagasawa M, Weijer K, Spits H, Blom B. The ETS transcription factor Spi-B is required for human plasmacytoid dendritic cell development. J Exp Med. 2004; 200:1503–9. https://doi.org/10.1084/jem.20041231 PMID:15583020

6. de Lau W, Kujala P, Schneeberger K, Middendorp S, Li VS, Barker N, Martens A, Hofhuis F, DeKoter RP, Peters PJ, Nieuwenhuis E, Clevers H. Peyer’s patch M cells derived from Lgr5(+) stem cells require SpiB and are induced by Rankl in cultured “miniguts”. Mol Cell Biol. 2012; 32:3639–47. https://doi.org/10.1128/MCB.00434-12 PMID:22778137

7. Kanaya T, Hase K, Takahashi D, Fukuda S, Hoshino K, Sasaki I, Hemmi H, Knoop KA, Kumar N, Sato M, Katsuno T, Yokosuka O, Toyooka K, et al. The Ets transcription factor Spi-B is essential for the differentiation of intestinal microfold cells. Nat Immunol. 2012; 13:729–36. https://doi.org/10.1038/ni.2352 PMID:22706340

8. Zhao X, Li L, Yuan S, Zhang Q, Jiang X, Luo T. SPIB acts as a tumor suppressor by activating the NFkB and JNK signaling pathways through MAP4K1 in colorectal cancer cells. Cell Signal. 2021; 88:110148. https://doi.org/10.1016/j.cellsig.2021.110148 PMID:34530056

9. Huang Q, Liu J, Wu S, Zhang X, Xiao Z, Liu Z, Du W. Spi-B Promotes the Recruitment of Tumor-Associated Macrophages via Enhancing CCL4 Expression in Lung Cancer. Front Oncol. 2021; 11:659131. https://doi.org/10.3389/fonc.2021.659131 PMID:34141615

10. Lenz N, Nagel I, Siebert R, Roschke AV, Sanger W, Wright GW, Dave SS, Tan B, Zhao H, Rosenwald A, Muller-Hermelink HK, Gascoyne RD, Campo E, et al. Aberrant immunoglobulin class switch recombination and switch translocations in activated B cell-like diffuse large B cell lymphoma. J Exp Med. 2007; 204:633–43. https://doi.org/10.1084/jem.20062041 PMID:17353367

11. Gjyshi A, Dash S, Cen L, Cheng CH, Zhang C, Yoder SJ, Teer JK, Armaiz-Pena GN, Monteiro ANA. Early transcriptional response of human ovarian and fallopian tube surface epithelial cells to norepinephrine. Sci Rep. 2018; 8:8291. https://doi.org/10.1038/s41598-018-26670-4 PMID:29844388

12. Lu JW, Hsia Y, Yang WY, Lin YI, Li CC, Tsai TF, Chang KW, Shieh GS, Tsai SF, Wang HD, Yuh CH. Identification of the common regulators for hepatocellular carcinoma induced by hepatitis B virus X antigen in a mouse model. Carcinogenesis. 2012; 33:209–19. https://doi.org/10.1093/carcin/bgr224 PMID:22021908

13. Zhao Y, Min L, Xu C, Shao L, Guo S, Cheng R, Xing J, Zhu S, Zhang S. Construction of disease-specific transcriptional regulatory networks identifies co-activation of four gene in esophageal squamous cell carcinoma. Oncol Rep. 2017; 38:411–7. https://doi.org/10.3892/or.2017.5681 PMID:28560409

14. Bajrai LH, Sohrab SS, Mobashir M, Kamal MA, Rizvi MA, Azhar EI. Understanding the role of potential pathways and its components including hypoxia and immune system in case of oral cancer. Sci Rep. 2021; 11:19576. https://doi.org/10.1038/s41598-021-98031-7 PMID:34599215
15. Jiang HB, Yang TJ, Lu P, Ma YJ. Gene expression profiling of gastric cancer. Eur Rev Med Pharmacol Sci. 2014; 18:2109–15. PMID:25070814

16. Ho YJ, Lin YM, Huang YC, Yeh KT, Lin LI, Lu JW. Tissue microarray-based study of hepatocellular carcinoma validating SPIB as potential clinical prognostic marker. Acta Histochim. 2016; 118:38–45. https://doi.org/10.1016/j.acthis.2015.11.005 PMID:26610895

17. O’Donnell JS, Teng MWL, Smyth MJ. Cancer immunoediting and resistance to T cell-based immunotherapy. Nat Rev Clin Oncol. 2019; 16:151–67. https://doi.org/10.1038/s41571-018-0142-8 PMID:30523282

18. Lonsdale J, Thomas J, Salvatore M, Phillips R, Lo E, Shad S, Hasz R, Walters G, Garcia F, Young N, Foster B, Moser M, Karasik E, et al, and GTEx Consortium. The Genotype-Tissue Expression (GTEx) project. Nat Genet. 2013; 45:580–5. https://doi.org/10.1038/ng.2653 PMID:23715323

19. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, Antipin Y, Reva B, Goldberg AP, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012; 2:401–4. https://doi.org/10.1158/2159-8290.CD-12-0095 PMID:22588877

20. Andersen PK, Gill RD. Cox’s Regression Model for Counting Processes: A Large Sample Study. Ann Stat. 1982; 10:1100–20. http://www.jstor.org/stable/2240714

21. Li T, Fu J, Zeng Z, Cohen D, Li J, Chen Q, Li B, Liu XS. TIMER2.0 for analysis of tumor infiltrating immune cells. Nucleic Acids Res. 2020; 48:W509–14. https://doi.org/10.1093/nar/gkaa407 PMID:32442275

22. Bonneville R, Krock MA, Kautoo EA, Miya J, Wing MR, Chen HZ, Reeser JW, Yu L, Roychowdhury S. Landscape of Microsatellite Instability Across 39 Cancer Types. JCO Precis Oncol. 2017; 1:1–15. https://doi.org/10.1200/PO.17.00073 PMID:29850653

23. Goodman AM, Sokol ES, Frampton GM, Lippman SM, Kurzrock R. Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy. Cancer Immunol Res. 2019; 7:1570–3. https://doi.org/10.1158/2326-6066.CIR-19-0149 PMID:31405947

24. Innocenti F, Ou FS, Qu X, Zemla TJ, Niedzwiecki D, Tam R, Mahajan S, Goldberg RM, Bertagnolli MM, Blanke CD, Sanoff H, Atkins J, Polite B, et al. Mutational Analysis of Patients With Colorectal Cancer in CALGB/SWOG 80405 Identifies New Roles of Microsatellite Instability and Tumor Mutational Burden for Patient Outcome. J Clin Oncol. 2019; 37:1217–27. https://doi.org/10.1200/JCO.18.01798 PMID:30865548

25. Wang J, Wang X, Guo Y, Ye L, Li D, Hu A, Cai S, Yuan B, Jin S, Zhou Y, Li Q, Zheng L, Tong Q. Therapeutic targeting of SPIB/PI1-facilitated interplay of cancer cells and neutrophils inhibits aerobic glycolysis and cancer progression. Clin Transl Med. 2021; 11:e588. https://doi.org/10.1002/ctm2.588 PMID:34841706

26. Takagi Y, Shimada K, Shimada S, Sakamoto A, Naoe T, Nakamura S, Hayakawa F, Tomita A, Kiyoi H. SPIB is a novel prognostic factor in diffuse large B-cell lymphoma that mediates apoptosis via the PI3K-AKT pathway. Cancer Sci. 2016; 107:1270–80. https://doi.org/10.1111/cas.13001 PMID:27348272

27. Andre F, Mardis E, Salm M, Soria JC, Siu LL, Swanton C. Prioritizing targets for precision cancer medicine. Ann Oncol. 2014; 25:2295–303. https://doi.org/10.1093/annonc/mdu478 PMID:25344359

28. Wood SL, Pernemalm M, Crosbie PA, Whetton AD. The role of the tumor-microenvironment in lung cancer-metastasis and its relationship to potential therapeutic targets. Cancer Treat Rev. 2014; 40:558–66. https://doi.org/10.1016/j.ctrv.2013.10.001 PMID:24176790

29. Junttila MR, de Sauvage FJ. Influence of tumour micro-environment heterogeneity on therapeutic response. Nature. 2013; 501:346–54. https://doi.org/10.1038/nature12626 PMID:24048067

30. Berntsson J, Nodin B, Eberhard J, Micke P, Jirström K. Prognostic impact of tumour-infiltrating B cells and plasma cells in colorectal cancer. Int J Cancer. 2016; 139:1129–39. https://doi.org/10.1002/ijc.30138 PMID:27074317

31. Carvajal-Hausdorf DE, Mani N, Velcheti V, Schalper KA, Rimm DL. Objective measurement and clinical significance of ID01 protein in hormone receptor-positive breast cancer. J Immunother Cancer. 2017; 5:81.
32. Feng M, Jiang W, Kim BYS, Zhang CC, Fu YX, Weissman IL. Phagocytosis checkpoints as new targets for cancer immunotherapy. Nat Rev Cancer. 2019; 19:568–86. https://doi.org/10.1038/s41568-019-0183-z PMID: 31462760

33. Rizzo A, Ricci AD, Brandi G. PD-L1, TMB, MSI, and Other Predictors of Response to Immune Checkpoint Inhibitors in Biliary Tract Cancer. Cancers (Basel). 2021; 13:558. https://doi.org/10.3390/cancers13030558 PMID: 33535621

34. Luchini C, Bibeau F, Ligtenberg MJL, Singh N, Nottegar A, Bosse T, Miller R, Riaz N, Douillard JY, Andre F, Scarpa A. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach. Ann Oncol. 2019; 30:1232–43. https://doi.org/10.1093/annonc/mdz116 PMID: 31056702

35. Shaffer AL, Emre NC, Romesser PB, Staudt LM. IRF4: Immunity. Malignancy! Therapy? Clin Cancer Res. 2009; 15:2954–61. https://doi.org/10.1158/1078-0432.CCR-08-1845 PMID: 19383829

36. Li SK, Abbas AK, Solomon LA, Groux GM, DeKoter RP. Nfkbeta1 activation by the E26 transformation-specific transcription factors PU.1 and Spi-B promotes Toll-like receptor-mediated splenic B cell proliferation. Mol Cell Biol. 2015; 35:1619–32. https://doi.org/10.1128/MCB.00117-15 PMID: 25733685

37. Huang YH, Cai K, Xu PP, Wang L, Huang CX, Fang Y, Cheng S, Sun XJ, Liu F, Huang JY, Ji MM, Zhao WL. CREBBP/EP300 mutations promoted tumor progression in diffuse large B-cell lymphoma through altering tumor-associated macrophage polarization via FBXW7-NOTCH-CCL2/CSF1 axis. Signal Transduct Target Ther. 2021; 6:10 https://doi.org/10.1038/s41392-020-00437-8 PMID: 33431788

38. Papavassiliou AG, Musti AM. The Multifaceted Output of c-Jun Biological Activity: Focus at the Junction of CD8 T Cell Activation and Exhaustion. Cells. 2020; 9:2470. https://doi.org/10.3390/cells9112470 PMID: 33202877

39. Peluso I, Yarla NS, Ambra R, Pastore G, Perry G. MAPK signalling pathway in cancers: Olive products as cancer preventive and therapeutic agents. Semin Cancer Biol. 2019; 56:185–95. https://doi.org/10.1016/j.semcancer.2017.09.002 PMID: 28912082

40. Hu J, Yu Y. The Function of Thioredoxin-Binding Protein-2 (TBP-2) in Different Diseases. Oxid Med Cell Longev. 2018; 2018:4582130. https://doi.org/10.1155/2018/4582130 PMID: 29854083

41. Son A, Nakamura H, Okuyama H, Oka S, Yoshihara E, Liu W, Matsuo Y, Kondo N, Masutani H, Ishii Y, Iyoda T, Inaba K, Yodoi J. Dendritic cells derived from TBP-2-deficient mice are defective in inducing T cell responses. Eur J Immunol. 2008; 38:1358–67. https://doi.org/10.1002/eji.200737939 PMID: 18425727

42. Xu YY, Jin R, Zhou GP, Xu HG. Involvement of GATA1 and Sp3 in the activation of the murine STING gene promoter in NIH3T3 cells. Sci Rep. 2017; 7:2090. https://doi.org/10.1038/s41598-017-02242-w PMID: 28522827

43. Bae JS, Park SH, Jamiyandorj U, Kim KM, Noh SJ, Kim JR, Park HJ, Kwon KS, Jung SH, Park HS, Park BH, Lee H, Moon WS, et al. CK2αi/CSNK2A1 Phosphorylates SIRT6 and Is Involved in the Progression of Breast Carcinoma and Predicts Shorter Survival of Diagnosed Patients. Am J Pathol. 2016; 186:3297–315. https://doi.org/10.1016/j.ajpath.2016.08.007 PMID: 27746184

44. Care MA, Cocco M, Laye JP, Barnes N, Huang Y, Wang M, Barrans S, Du M, Jack A, Westhead DR, Doody GM, Tooze RM. SPIB and BATF provide alternate determinants of IRF4 occupancy in diffuse large B-cell lymphoma linked to disease heterogeneity. Nucleic Acids Res. 2014; 42:7591–610. https://doi.org/10.1093/nar/gku451 PMID: 24875472
Supplementary Figure 1. Mutation of SPIB in pan-cancer. Analysis of genetic alteration type and mutation frequency of SPIB in different cancers based on the cBioPortal database.
Supplementary Figure 2. Relationship between SPIB expression and progression-free interval (PFI) in pan-cancer. (A) Cox regression analysis of SPIB in 44 tumors. (B) Kaplan-Meier OS curves of SPIB expression in patients with GBMLGG, LGG, KIRP, KIPAN, GBM and UVM. (C) Kaplan-Meier OS curves of SPIB expression in patients with BRCA, LUAD, HNSC, SKCM, SKCM-M and OV. The vertical coordinate is the survival probability and the horizontal coordinate is the survival time (days).
Supplementary Figure 3. Co-expression of TREM2 and immune-related genes, including five immune pathways chemokine (41), receptor (18), MHC (21), Immunoinhibitor (24), Immunostimulator (46) marker genes. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
Supplementary Tables

Please browse Full Text version to see the data of Supplementary Tables 1–4 and 6.

Supplementary Table 1. Pan-cancer dataset.

Supplementary Table 2. Prognosis analysis.

Supplementary Table 3. Immune cell infiltration.

Supplementary Table 4. ESTIMATE.

Supplementary Table 5. Co-expression analysis of immune regulatory genes.

| CODE  | SampleNum | SigCount | PositiveCount | NegativeCount |
|-------|-----------|----------|---------------|---------------|
| SKCM  | 102       | 114      | 114           | 0             |
| KIPAN | 884       | 143      | 143           | 0             |
| UVM   | 79        | 123      | 123           | 0             |
| LIHC  | 369       | 142      | 139           | 3             |
| BLCA  | 407       | 137      | 136           | 1             |
| KIRC  | 530       | 139      | 139           | 0             |
| KIRP  | 288       | 131      | 131           | 0             |
| OV    | 419       | 146      | 146           | 0             |
| PCPG  | 177       | 135      | 135           | 0             |
| KICH  | 66        | 125      | 124           | 1             |
| THCA  | 504       | 140      | 138           | 2             |
| BRCA  | 1092      | 140      | 139           | 1             |
| PRAD  | 495       | 143      | 142           | 1             |
| HNSC  | 518       | 140      | 129           | 11            |
| LUSC  | 498       | 130      | 126           | 4             |
| CESC  | 304       | 127      | 123           | 4             |
| LUAD  | 513       | 138      | 135           | 3             |
| ACC   | 77        | 113      | 110           | 3             |
| TGCT  | 148       | 111      | 110           | 1             |
| UCEC  | 180       | 106      | 106           | 0             |
| CHOL  | 36        | 67       | 66            | 1             |
| NB    | 153       | 126      | 123           | 3             |
| PAAD  | 178       | 137      | 136           | 1             |
| MESO  | 87        | 102      | 102           | 0             |
| READ  | 92        | 107      | 106           | 1             |
| COAD  | 288       | 128      | 128           | 0             |
| COADREAD | 380 | 133      | 133           | 0             |
| ALL   | 132       | 33       | 30            | 3             |
| DLBC  | 47        | 11       | 10            | 1             |
| THYM  | 119       | 112      | 107           | 5             |
| ESCA  | 181       | 110      | 103           | 7             |
| STAD  | 414       | 115      | 109           | 6             |
| STES  | 595       | 130      | 119           | 11            |
|          |       |     |     |     |
|----------|-------|-----|-----|-----|
| SARC     | 258   | 99  | 91  | 8   |
| UCS      | 57    | 37  | 36  | 1   |
| GBM      | 153   | 115 | 115 | 0   |
| GBMLGG   | 662   | 138 | 135 | 3   |
| LGG      | 509   | 128 | 127 | 1   |
| LAML     | 173   | 93  | 90  | 3   |
| WT       | 120   | 58  | 57  | 1   |

Supplementary Table 6. Enrichment analysis.